Table 1 (abstract P21). Primary and secondary outcome measures in erenumab-treated responder and nonresponder subgroups in STRIVE
Erenumab 70 mg | Responders (n=135), baseline | Responders, change | Non responders (n=161), baseline | Non responders change | Overall (n=312), baseline | Overall, change (mean±SE) |
MMD | 8.3 ±2.5 | −6.1 ±2.1 | 8.3 ±2.4 | −1.1 ±2.8 | 8.3 ±2.5 | −3.4 ±0.2 |
MSMD | 2.9 ±3.3 | −2.0 ±2.4 | 3.8 ±3.5 | −0.4 ±2.0 | 3.2 ±3.4 | −1.1 ±0.1 |
MPFID-EA | 13.5 ±8.5 | −9.9 ±6.8 | 14.1 ±8.9 | −2.4 ±7.0 | 14.0 ±8.9 | −5.8 ±0.5 |
MPFID-PI | 11.8 ±9.3 | −8.4 ±7.00 | 12.7 ±9.6 | −1.1 ±7.7 | 12.6 ±9.7 | −4.4 ±0.5 |
Erenumab 140 mg | Responders (n=159), baseline | Responders, change | Non responders (n=143), baseline | Non responders change | Overall (n=318), baseline | Overall, Change (mean±SE) |
MMD | 8.2 ±2.4 | −6.0 ±2.1 | 8.5 ±2.5 | −1.4 ±2.3 | 8.3 ±2.5 | −3.8 ±0.2 |
MSMD | 3.2 ±3.4 | −2.3 ±2.6 | 3.6 ±3.5 | −0.9 ±1.7 | 3.4 ±3.5 | −1.6 ±0.1 |
MPFID-EA | 12.6 ±7.9 | −8.9 ±6.8 | 13.6 ±8.6 | −2.5 ±7.0 | 13.0 ±8.2 | −5.8 ±0.4 |
MPFID-PI | 11.5 ±8.3 | −7.6 ±7.0 | 12.8 ±9.7 | −1.8 ±8.00 | 12.0 ±9.0 | −4.8 ±0.5 |